Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + degarelix + bicalutamide
- Development stage
- Unknown
- Lead developer
- University of Wisconsin–Madison
- Modality
- Peptides, Small Molecules
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
This drug combination is a neoadjuvant chemohormonal therapy regimen being evaluated by the University of Wisconsin, Madison, for the treatment of high-risk or oligometastatic prostate cancer. The regimen consists of **docetaxel**, a taxane chemotherapy that stabilizes microtubules to induce cell cycle arrest; **degarelix**, a gonadotropin-releasing hormone (GnRH) receptor antagonist that rapidly suppresses serum testosterone; and **bicalutamide**, a non-steroidal androgen receptor antagonist. This multimodality approach is administered prior to radical prostatectomy to evaluate pathologic complete response rates and improve clinical outcomes in patients with aggressive localized or limited metastatic disease. The trial specifically investigates the synergy between rapid androgen deprivation and cytotoxic chemotherapy in the neoadjuvant setting.
- Brand names
- TaxotereFirmagonCasodex
- Other names
- Neoadjuvant Chemohormonal TherapyDocetaxel/Degarelix/Bicalutamide Combination
02
Targets
AR (Adrenergic receptors)GnRHR (Gonadotropin-releasing hormone receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel + degarelix + bicalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + degarelix + bicalutamide.